Core Viewpoint - The announcement indicates that Ying'en Biotechnology-B (09606.HK) will be included in the Hang Seng Composite Index and the Stock Connect program starting September 8, 2025, reflecting strong market recognition of the company's performance and value [1] Group 1 - The inclusion in the Hang Seng Composite Index and Stock Connect signifies a significant endorsement from the capital market [1] - This move allows qualified investors from mainland China to directly invest in the company's shares listed on the Hong Kong Stock Exchange through the Shanghai Stock Exchange [1] - The anticipated inclusion is expected to broaden the company's investor base and potentially increase the trading liquidity of its shares [1]

Duality Biotherapeutics, Inc. 映恩生物 （根據開曼群島法律註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 自願性公告 本公告由映恩生物（「本公司」）作出，旨在向其股東及潛在投資者提供有關本公司 最新發展動態的資料。 香港，2025年9月7日 （股份代號：9606） 納入恒生綜合指數成份股 及獲調入港股通證券名單 本公司董事會（「董事會」）欣然宣佈，自2025年9月8日起，本公司股份（「股份」） 將(i)獲恒生指數有限公司納入恒生綜合指數成份股及(ii)被調入滬港通下港股通標 的名單。 股份獲納入恒生綜合指數及滬港通合資格證券，代表資本市場對本公司表現及價 值的高度認同，中國內地合資格投資者從而可以透過上海證券交易所直接投資於 香港聯合交易所有限公司上市的股份。預期該項納入將進一步擴大本公司的投資 者基礎，並有望增加股份的交易流通量。 承董事會命 映恩生物 董事會主席、執行董事兼首席執行官 朱忠遠博士 於 ...

Core Insights - BioNTech has achieved a successful mid-stage analysis for an experimental drug in collaboration with InnoCare Pharma, showing better results in breast cancer treatment compared to Roche's established drug Kadcyla [1] - The trial involved 228 patients in China who had metastatic cancer and were previously treated with chemotherapy and trastuzumab [1] - This success marks BioNTech's first significant outcome in a late-stage trial for its cancer compounds, which are crucial for the company's future growth [1] Company Developments - BioNTech's collaboration with InnoCare Pharma has resulted in its first successful outcome in a late-stage trial, indicating potential for regulatory approval [1] - The company has previously generated billions in revenue through its COVID-19 vaccine partnership with Pfizer [1] - InnoCare Pharma focuses on developing antibody-drug conjugates (ADCs) and has established partnerships with other companies like GlaxoSmithKline and Avenzo Therapeutics [1] Market Reaction - Following the news of the successful trial, InnoCare Pharma's stock has surged over 280% since its listing in Hong Kong in April [2] - BioNTech's stock rose nearly 7% in pre-market trading following the announcement [2]

Core Viewpoint - The announcement indicates that the clinical trial for DB-1303/BNT323 has met its primary endpoint of progression-free survival (PFS) compared to the control group in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane treatments [1] Group 1: Clinical Trial Details - The trial is a randomized, controlled, open-label, multi-center Phase III clinical study conducted in China [1] - The objective of the trial is to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in the specified patient population [1] Group 2: Regulatory Plans - Following the interim analysis results, the company plans to communicate with the Center for Drug Evaluation of the National Medical Products Administration in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]

Core Viewpoint - The company, InnoCare Pharma, has announced that its drug DB-1303/BNT323 has met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes [1] Group 1 - The independent data monitoring committee (IDMC) evaluated the trial and confirmed the positive results compared to the control group [1] - The company plans to communicate with the National Medical Products Administration (NMPA) in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]

Core Viewpoint - The company, InnoCare Pharma-B (09606), announced that its DB-1303/BNT323 has met the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes, as evaluated by an independent data monitoring committee (IDMC) [1] Group 1 - The Phase III clinical trial is a randomized, controlled, open-label, multi-center study conducted in China [1] - The trial aims to assess the efficacy and safety of DB-1303 compared to T-DM1 in the specified patient population [1] - Following the interim analysis results, the company plans to communicate with the National Medical Products Administration (NMPA) in China regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 Duality Biotherapeutics, Inc. 映恩生物 （根據開曼群島法律註冊成立的有限公司） （股份代號：9606） 內幕消息 DB-1303/BNT323用於HER2陽性不可切除或 轉移性乳腺癌患者的III期臨床試驗達到主要研究終點 緒言 本公告由映恩生物（「本公司」）根據香港聯合交易所有限公司證券上市規則（「上市 規則」）第13.09條及香港法例第571章證券及期貨條例第XIVA部內幕消息條文作 出。 根據這項中期分析結果，本公司計劃與中國國家藥品監督管理局（國家藥監局）藥 品審評中心（藥審中心）就提交DB-1303/BNT323生物製品上市許可申請(BLA)進 行溝通。 該臨床試驗之設計、目的及結論 該試驗是一項在中國進行的隨機、對照、開放標籤、多中心的III期臨床試驗，旨 在評估DB-1303相較於T-DM1在既往接受曲妥珠單抗和紫杉烷類治療的HER2陽 性不可切除或轉移性乳腺癌患者 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 映恩生物 (「本公司」) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 09606 說明 法定/註冊股份數目 面值 法定/註冊股本 | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 200,000,000 | USD | 0.0001 | USD | | 20,000 | | 增加 / 減少 (-) | | | | | USD | | | | 本月底結存 | | 200,000,000 USD | | 0.0001 | USD | | 20,000 | 本月底法定/註冊股本總額： USD 20,000 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 II. 已發行股份 ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Viewpoint - Incyte Biosciences-B (09606) reported a significant increase in revenue and profit for the first half of the year, driven by external licensing and collaboration agreements, despite not having any commercialized products yet [1] Financial Performance - The company achieved a revenue of approximately 1.229 billion RMB, representing a year-on-year growth of 22.9% [1] - Adjusted profit for the period was around 146 million RMB, reflecting a year-on-year increase of 14.2% [1] Strategic Partnerships - The revenue growth was primarily fueled by licensing and collaboration fees [1] - Incyte has established extensive partnerships with companies such as BioNTech, BeiGene, and GlaxoSmithKline, with a potential total transaction value exceeding 6 billion USD [1] - These collaborations are expected to provide ongoing financial support as clinical projects progress [1]